NEW Zealand’s PHARMAC has
confirmed it will fund MSD’s
melanoma drug pembrolizumab
(Keytruda) from 01 Sep, in the light
of new clinical evidence which has
given it the “confidence we needed
to progress the funding decision”.
“PHARMAC has been able to
adapt to an evolving evidence base
and changes in affordability that
have come with our negotiations
with MSD and an increase in the
medicines budget,” said PHARMAC
director of operations Sarah Fitt.
The deal will also see PHARMAC
fund a modified-release tablet form
of posaconazole (Noxafil) effective
01 Sep.
Fitt said the move “reflects the
flexibility of the PHARMAC model,
while allowing us to make the high quality
decisions New Zealanders
expect.”The above article was sent to subscribers in Pharmacy Daily's issue from 03 Aug 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Aug 16
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.